WHO grants nonproprietary name to ovarian cancer cell therapy
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The…
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The…
Regulators in the U.S. and Europe have approved updates to the prescribing information for Carvykti (ciltacabtagene autoleucel), a cell therapy …
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1…
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as…
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to daraxonrasib, an oral therapy being developed by Revolution Medicines to treat…
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
November is Pancreatic Cancer Awareness Month, and advocates nationwide are hosting events to unite the community and raise awareness about the condition. For this year’s…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
Specific genetic changes in small populations of tumor cells can help to make ovarian cancer resistant to treatment, a new study by U.S. researchers revealed.